局部消融联合EGFR-TKI一线治疗晚期EGFR突变NSCLC的系统综述与荟萃分析
该系统综述与荟萃分析纳入31项研究(24项比较性研究,含6项随机研究),评估一线EGFR-TKI联合局部消融治疗晚期EGFR突变NSCLC的疗效与安全性。结果显示联合治疗显著改善无进展生存期(HR=0.45,95%CI:0.37-0.55)和总生存期(HR=0.52,95%CI:0.40-0.67),毒性可接受,但需进一步前瞻性研究明确患者选择与最佳时机。
要点
- 一线EGFR-TKI联合局部消融显著改善PFS(HR=0.45)和OS(HR=0.52)。
- 获益在寡转移和未选择人群、 upfront和巩固策略中一致。
- 放射性肺炎更常见,但≥3级事件不常见,无意外安全信号。
核心结论
- 在异质性证据基础上,一线EGFR-TKI联合局部消融与改善PFS和OS相关,毒性可接受。
- 研究结果支持进一步前瞻性研究以明确患者选择、最佳时机及与当代系统联合策略的整合。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Embase和Elicit至2025年12月,方案注册于PROSPERO(CRD420251244650)。
- 共纳入31项研究,其中24项比较性研究(6项随机、2项前瞻性非随机、16项回顾性),单臂和非比较性研究进行描述性分析。
主要发现
- 与单用EGFR-TKI相比,联合局部消融显著改善无进展生存期(HR=0.45,95%CI:0.37-0.55)。
- 联合局部消融显著改善总生存期(HR=0.52,95%CI:0.40-0.67)。
- 获益在寡转移和未选择人群、upfront和巩固策略、局部消融部位(原发灶±转移灶)、TKI代际以及前瞻性和回顾性研究中一致。
- 放疗相关毒性(尤其肺炎)在联合局部消融时更常见,但≥3级事件不常见,未出现意外安全信号。
临床怎么用
- 对于晚期EGFR突变NSCLC患者,一线EGFR-TKI联合局部消融可作为改善疾病控制的治疗选择,但需注意放射性肺炎风险。
- 患者选择、局部消融最佳时机及其与当代系统联合策略的整合仍需前瞻性研究进一步明确。
局限性
- 证据基础异质性较大,比较性研究中仅6项为随机研究,多数为回顾性研究。
- 单臂和非比较性研究仅作描述性分析,未纳入定量荟萃分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Systemic intensification strategies improve outcomes in advanced EGFR-mutated NSCLC but increase toxicity. Integrating local ablative therapy (LAT) with first-line EGFR tyrosine kinase inhibitor (TKI) monotherapy represents an alternative approach to enhance disease control while preserving long-term tolerability. METHODS: MEDLINE, Embase, and Elicit were searched to December 2025. The protocol was registered in PROSPERO (CRD420251244650). Randomized and nonrandomized comparative studies evaluating EGFR TKI with or without LAT integrated into first-line treatment, either upfront or as consolidative therapy, were included in quantitative meta-analyses. Single-arm and noncomparative studies were analyzed descriptively. Hazard ratios (HRs) were pooled using random-effects models. Prespecified subgroup analyses explored disease burden, LAT timing, study design (prospective versus retrospective), LAT site, and TKI generation. RESULTS: A total of 31 studies met the inclusion criteria, including 24 comparative studies (six randomized, two prospective nonrandomized, and 16 retrospective). LAT integration significantly improved progression-free survival (HR = 0.45, 95% confidence interval: 0.37-0.55) and overall survival (HR = 0.52, 95% confidence interval: 0.40-0.67) versus EGFR TKI alone. Benefits were consistent across oligometastatic and unselected populations, upfront and consolidative strategies, LAT sites (primary tumor with or without metastatic sites), TKI generations, and prospective and retrospective studies. Radiotherapy-related toxicities, particularly pneumonitis, were more frequent with LAT, but grade more than or equal to 3 events were uncommon and no unexpected safety signals emerged. CONCLUSIONS: Across a heterogeneous evidence base, integrating LAT into first-line EGFR TKI therapy is associated with improved progression-free survival and overall survival with acceptable toxicity. These findings support further prospective investigation to better define patient selection, optimal timing, and integration with contemporary systemic combination strategies.
引用
- Brunetti L, Colella G, Di Fazio GR, et al. First-Line Integration of Local Ablative Therapy With EGFR Tyrosine Kinase Inhibitors in Advanced EGFR+ NSCLC: A Systematic Review and Meta-Analysis. J Thorac Oncol. 2026. PMID: 42025696. doi:10.1016/j.jtho.2026.103735
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。